Lionheart Health, Inc., a company focused on bioelectric regenerative medicine and healthspan optimization, today announced that enrollment is beginning for its Lionheart Klotho-Up™ Study, a longitudinal program designed to assess whether a practical, structured wellness and bioelectric intervention program may help support key markers of healthy aging.

The Lionheart Klotho-Up™ Study is built around two core required program elements:

1. Daily Klotho-favoring meals, supplements, and beverages designed to support a biologically favorable environment for healthy aging; and
2. BodStim™ Klotho-enhancing exercise performed two or three times per week for one hour per session.

Participants may also choose to add from a broader menu of optional supportive therapies, which may include hyperbaric oxygen therapy, red light therapy, cold therapy, pulsed electromagnetic field (PEMF) therapy, organ-targeted bioelectric stimulation, and other wellness-supportive interventions depending on availability, candidacy, and site offerings.

“Lionheart’s goal is to make a Klotho-supportive lifestyle and bioelectric wellness program more structured, measurable, and accessible,” said Howard Leonhardt, Executive Chairman and co-CEO of Lionheart Health. “We believe many people want more than vague longevity advice. They want a guided program, objective testing, and the opportunity to track whether their efforts, including technological interventions such as bioelectric controlled protein expressions, are improving meaningful indicators of muscle, cognitive, and immune health over time.”

All participants in the Lionheart Klotho-Up™ Study must complete a formal informed patient consent process and agree to required baseline and one-year follow-up assessments. Required core assessments include:

1. Muscle Health

• Grip strength
• Gait speed
• 6-minute walk test
• Muscle mass assessment

2. Brain Health

• Standardized cognitive testing
• Memory testing
• Mood assessment

3. Immune Health

• Gut intelligence testing
• Various immune and wellness-related biomarkers

In addition, all participants must complete a 461 blood biomarker panel at baseline and again at one year. Participants may also elect to add biomarker testing at 3 months and 6 months, and in some cases an additional test at approximately 4 weeks may be recommended to help optimize supplements and program adherence.

An AI-enhanced MRI through CoreViva will also be available on an optional basis for participants seeking deeper body composition and imaging-based insights.

For selected candidates at certain outside the United States (OUS) affiliated sites, biologic therapies may also be available. These therapies would require a separate, higher-risk informed patient consent and would only be offered where legally permissible, medically appropriate, and under the oversight of the applicable treating clinicians and site protocols.

Why Klotho Matters

Klotho is widely recognized as an important longevity-associated protein linked to multiple aspects of healthy aging. It has been associated with support for:

• Healthy muscle function and physical resilience
• Brain health, cognition, and neurological vitality
• Vascular and metabolic health
• Inflammation balance and cellular stress response
• Overall healthy aging biology

Many individuals may wish to improve or support Klotho-related biology as part of a broader effort to maintain strength, mobility, energy, cognitive sharpness, and immune resilience with age.

The Lionheart Klotho-Up™ Study is intended to help participants and clinicians evaluate how a structured program of nutrition, supplementation, bioelectric exercise, and optional supportive therapies may correlate with measurable changes over time.

Enrollment is now opening on a limited basis for qualified participants at licensed clinics locations. This is a subsidized paid registry study. Patients will pay $12.99 a day for health fresh klotho favoring meals delivered to their home daily or can choose to shop themselves following recipes sent to save costs (will cut costs to about $5 to $7 per meal). If patients make their own meals they need to take a photo to upload to the study database daily. The BodStim™ EMS suit can be leased for 1 year with $890 down payment and monthly payments of $188. The 461 biomarker test is $800 each for non-members and $463 for members. The study sponsor Lionheart Health, Inc. will cover ALL muscle, brain and immunity health test assessments at baseline and 1 year. If patient selects to add voluntarily testing at 3 months and 6 months they will pay cost to cost for those extra tests. Optional AI enhanced MRI scans also will be covered by patients.

This study also supports Lionheart Health’s participation in XPRIZE Healthspan, where Lionheart Health Inc. was named a Top 40 Milestone 1 awardee semi-finalist from more than 600 registered teams worldwide, reflecting the strength of its proposed therapeutic approach, preliminary data and clinical testing strategy.

For more information about the Lionheart Klotho-Up™ Study, eligibility, participating sites, and informed consent requirements, contact Lionheart Health at Email Contact or visit Lionheart Longevity at https://www.LionheartLongevity.com to BOOK A VIDEO CONSULTATION with one of our trusted clinicians.

Contact
Lionheart Health, Inc.

https://www.LionheartLongevity.com

email: Email Contact

Important Notice: The Lionheart Klotho-Up™ Study is intended for research, wellness and health optimization purposes. Participation requires informed consent. Individual results may vary. Optional therapies are not available to all participants and may be subject to additional eligibility criteria, regulatory limitations, and separate consent requirements. This announcement is not intended as medical advice or as a claim of diagnosis, treatment, cure, or prevention of disease. Any early stage pilot clinical data communicated may not hold up in full scale statistically significant controlled studies.

Howard J. Leonhardt

Executive Chairman & co-CEO

Lionheart Health, Inc.

Leonhardt Ventures LLC

21060 Pacific City Cir 6115

Huntington Beach, CA 92648

R&D Lab 5270 California. Avenue, Irvine, CA 92617

Research Clinic and Training Center for Licensed Clinics

4440 Von Karman, Ste 100

Newport Beach, CA 92660

https://www.leonhardtventures.com

https://www.lionhearthealthstim.com

https://www.lionheartlongevity.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., a leader in bioelectric regenerative medicine and healthspan optimization technologies, is proud to announce that Joseph C. Maroon, MD, FACS, has joined its Scientific and Clinical Advisory Board.

Dr. Maroon is a board-certified neurosurgeon and internationally recognized authority in brain health, sports neurosurgery, concussion management, neuroinflammation, and longevity science. He is Clinical Professor of Neurosurgery at the University of Pittsburgh Medical Center (UPMC) and has served for decades as Team Neurosurgeon for the Pittsburgh Steelers. Dr. Maroon is also a prolific researcher and author, widely respected for his work in preventive neurology, functional medicine, and healthspan science.

As an author, Dr. Maroon has advanced global awareness of performance longevity and inflammation reduction through best-selling books including Square One, which emphasizes foundational strategies for optimizing long-term brain and body health.

Strengthening Lionheart’s Brain & Healthspan Platform

Dr. Maroon’s appointment reinforces Lionheart Health’s commitment to advancing evidence-based bioelectric stimulation therapies designed to:

• Improve cognition, memory, and mood

• Support neuroplasticity and neurotrophic signaling (e.g., BDNF pathways)

• Reduce systemic and neuroinflammation

• Enhance muscle-brain axis signaling

• Elevate circulating regenerative proteins linked to healthy aging

Lionheart Health’s multi-modality platform—including BodStim™, Brain Band™, and other patented bioelectric stimulation technologies—aligns closely with Dr. Maroon’s life-long focus on neuroprotection, inflammation reduction, and performance longevity.

“Dr. Maroon’s decades of leadership in neurosurgery and preventive brain health bring exceptional scientific credibility and clinical insight to Lionheart Health,” said Howard Leonhardt, Founder and Executive Chairman of Lionheart Health, Inc. “His work bridging neuroscience, inflammation control, and longevity science aligns perfectly with our mission to increase healthspan through measurable improvements in muscle, brain, and immune function.”

Advancing Healthspan Science

Lionheart Health is currently advancing multiple clinical initiatives focused on improving functional biomarkers of aging—including grip strength, gait speed, cognition, memory, inflammatory markers, and regenerative protein expression. Dr. Maroon will advise on:

• Brain health clinical study design

• Neurocognitive endpoint validation

• Concussion and neuroinflammation applications

• Translation of regenerative signaling science into clinical protocols

• Integration of lifestyle, supplementation, and bioelectric strategies for healthspan extension

Dr. Maroon commented:

“Optimizing brain health is central to extending meaningful healthspan. I look forward to supporting Lionheart Health’s efforts to scientifically validate innovative bioelectric therapies that aim to improve neurological resilience, reduce inflammation, and enhance overall vitality.”

Lionheart Health’s expanding intellectual property portfolio includes patents and patent-pending technologies targeting key regenerative and neuroprotective signaling pathways, including Klotho, Brain-Derived Neurotrophic Factor (BDNF), GDF10, SDF-1, PDGF, and eNOS. These pathways are widely recognized for their roles in neuroplasticity, synaptic resilience, angiogenesis, stem cell homing, endothelial health, and inflammation modulation—all critical components of preserving and enhancing brain function during aging. Through its patented bioelectric stimulation platforms, including Brain Band™ and BodStim™, Lionheart Health aims to modulate these regenerative protein expressions to support cognitive performance, memory retention, mood stability, and neurovascular integrity. Brain health represents one of the three core pillars in which Lionheart Health is competing in the Semi-Finals of the $101M XPRIZE Healthspan Competition. Lionheart Health's Brain Band™ was recently awarded a prestigious UCI Capstone Grant, providing a multidisciplinary team of five University of California, Irvine engineering PhD-level researchers who worked over a seven-month period to advance device optimization and signal validation. Medtech Outlook Magazine recognized Lionheart Health as 2025 Micro Stimulator Developer of the Year. Lionheart Health recently also won the coveted Abbvie Allergan ULP Innovation Award and in 2025 were finalists in both the Orange County Business Journal's Innovator of Year Awards and Octane's Life Sciences Technology Company of Year Award. Lionheart Health has completed successful pre-clinical studies at AccuLab Life Sciences in San Diego with grant and credit line support, as well as a successful pilot clinical study in Brazil, further strengthening the scientific foundation of its neuro-regenerative platform. The company is preparing to enroll soon in a combination BodStim TM bioelectric stimulation exercise suit and Brain Band TM clinical trial for brain health. Both of these therapies have separately demonstrated statistically significant improvements in brain health in previous stand alone studies.

Dr. Maroon brings more than four decades of leadership in academic neurosurgery, clinical innovation, and performance medicine. A board-certified neurosurgeon and Fellow of the American College of Surgeons (FACS), he has performed thousands of complex brain and spine procedures and is internationally recognized for advancing minimally invasive neurosurgical techniques. Throughout his tenure at the University of Pittsburgh Medical Center (UPMC), he has helped shape modern standards in concussion management, traumatic brain injury care, and sports-related neurological safety. He has served for decades as Team Neurosurgeon for the Pittsburgh Steelers and has been a trusted neurological consultant to elite athletes worldwide.

In addition to his clinical accomplishments, Dr. Maroon is a prolific scientific author with more than 300 peer-reviewed publications and multiple textbooks in neurosurgery, inflammation science, and sports medicine. His research has contributed to deeper understanding of neuroinflammation, omega-3 fatty acids in brain protection, performance longevity, and integrative strategies for preserving cognitive function across the lifespan. His thought leadership extends beyond academic medicine through numerous keynote presentations, advisory roles, and public education initiatives focused on proactive brain health and extending meaningful healthspan.

Dr. Maroon’s unique combination of surgical excellence, scientific rigor, and preventive longevity advocacy aligns directly with Lionheart Health’s mission to elevate regenerative signaling and measurable functional performance as central strategies for extending healthy years of life.

About Lionheart Health, Inc.

Lionheart Health, Inc. is a regenerative medicine and bioelectric stimulation company focused on extending healthspan through patented, non-invasive and minimally invasive technologies designed to activate regenerative signaling pathways. The company’s platform targets improvements in muscle strength, cognitive function, metabolic health, immune resilience, and overall vitality.

Lionheart Health operates licensed longevity and wellness clinics and collaborates with academic institutions and clinical partners to generate peer-reviewed data supporting its innovative therapies.

Media Contact:
Lionheart Health, Inc.
www.LionheartLongevity.com + www.LionheartHealthstim.com

email: CS@LionheartHealthStim.com

Forward-Looking Statements: This press release contains forward-looking statements regarding clinical development, regulatory pathways, and anticipated health outcomes. Actual results may differ materially based on ongoing research and regulatory review.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., with Leonhardt Ventures LLC, today announced it has received a Letter of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled “Modulation of Growth Differentiation Factor 10 (GDF10) and BDNF” (Publication No. 20230133737; Application No. 18/051,425).

The allowed claims cover a low-voltage, pulsed bioelectric stimulation system programmed to upregulate the expression and/or release of Growth Differentiation Factor 10 (GDF10) and Brain Derived Neurotrophic Factor (BDNF) in target tissues. The application was filed October 31, 2022, and published May 4, 2023. The inventors are Howard J. Leonhardt and neuroscientist Kelsie Leonhardt.

The allowed claims include bioelectric signaling at 2 mA to 4 mA direct current positive polarity, including optimized stimulation at approximately 3 mA positive polarity, measured at the target tissue level. The patent also includes programmable stimulation to enhance expression of complementary regenerative proteins including Klotho, stromal cell-derived factor 1 (SDF1), and insulin-like growth factor 1 (IGF-1).

GDF10 has been identified in preclinical research as a signaling protein associated with axonal sprouting and neural network repair following ischemic stroke. Lionheart Health’s patented bioelectric platform is designed to stimulate endogenous repair pathways without systemic drug exposure.

Pre-Clinical & Pilot Clinical Validation

Lionheart Health has completed pre-clinical animal studies and a pilot clinical study in Brazil utilizing its Brain Band™ platform incorporating GDF10 and BDNF signaling protocols.

Pre-Clinical Study – San Diego (AccuLab Life Sciences, with Research Grant Support)
• Successful completion of safety and feasibility validation in animal models
• Demonstrated measurable modulation of regenerative signaling pathways
• Confirmed activation of neuroplasticity-related proteins including Klotho, BDNF, GDF10, and SDF-1
• Established translational foundation for human pilot evaluation
• Follow-on optimization supported through a University of California Irvine Capstone Research Grant involving five PhD-level engineers over seven months

Pilot Clinical Study – Brazil (Brain Band™ Program)
Participants receiving non-invasive bioelectric brain stimulation demonstrated:
• Improvements in cognition
• Improvements in memory
• Improvements in mood
• Reduction in depression symptoms

The pilot study provided early human validation of non-invasive bioelectric modulation targeting regenerative protein pathways. Functional improvements were observed alongside mechanistic protein-target signaling strategies.

Brain Band™ programming included DepressiStim™, MemoryStim™, CerebraCell™, and AddictiStim™ protocols and forms part of Lionheart Health’s KLOTHO-UP Study currently competing in the Semi-Finals of the $101 million XPRIZE Healthspan competition.

Investigational Applications

Potential investigational applications disclosed in the patent include:

Neurological & Brain Health
• Stroke rehabilitation
• Traumatic brain injury recovery
• Alzheimer’s disease (investigational)
• Parkinson’s disease (investigational)
• Essential tremors
• Anxiety disorders
• Brain cancer adjunct therapy

Muscle & Mobility Health
• Post-stroke motor recovery
• Functional strength improvement
• Gait speed enhancement
• 6-minute walk performance improvement
• Sarcopenia mitigation (investigational)

Immune & Regenerative Resilience
• Tissue repair coordination
• Inflammatory resolution support
• Cellular recovery signaling
• Organ resilience after injury

Vascular & Circulatory Health
• Vascular remodeling research
• Endothelial repair signaling
• Post-ischemic tissue recovery

Liver & Metabolic Health (Investigational)
The patent includes liver tissue targeting. Mechanistic rationale includes:
• TGF-β superfamily involvement in hepatic regeneration
• Hepatic tissue remodeling pathways
• Fibrosis modulation research
• Metabolic resilience enhancement

Liver health plays a central role in systemic inflammation control, insulin sensitivity, detoxification, and metabolic stability — core determinants of healthspan longevity.

Additional tissue targets include retina, cochlea, bone, adipose tissue, lung, prostate, uterus, spleen, and other organs.

“This allowance represents a significant milestone in our mission to harness bioelectric signaling to activate the body’s own regenerative repair systems,” said Howard J. Leonhardt, Executive Chairman of Lionheart Health. “By precisely modulating GDF10 and synergistic proteins such as Klotho and BDNF, we believe we can accelerate recovery in stroke and other neurological conditions while supporting broader healthspan optimization.”

The issuance of this patent strengthens Lionheart Health’s expanding intellectual property portfolio in bioelectric regenerative medicine and supports the company’s multi-protein regenerative platform strategy focused on brain health, muscle function, vascular recovery, liver resilience, and systemic longevity.

About Lionheart Health, Inc.

Lionheart Health, Inc., operating in collaboration with Leonhardt Ventures LLC, is a bioelectric regenerative medicine company developing patented technologies designed to modulate endogenous protein expression to support tissue repair, neuroplasticity, vascular recovery, metabolic resilience, and healthspan optimization. This includes research protocols for bioelectric enhanced biologics and micro implantable stimulators and re-fillable infusion pumps. The flagship devleopment of the company is a whole body regeneration system currently in pre-clinical studies. The company’s platform technologies include Brain Band™, BodStim™, OrthoStim™, SkinStim™, HairCell™, EyeCell™, ErectiStim TM, FemStim TM, TestiStim TM, PressureStim TM, Stem Cell Bra TM (many still in investigational research stage) and additional programmable bioelectric systems targeting multi-organ regenerative signaling pathways. Lionheart Health integrates bioelectric stimulation with biomarker-guided protocols and is advancing clinical research programs aligned with functional healthspan endpoints, including mobility, cognition, muscle strength, and systemic resilience. The company is currently a Semi-Finalist competitor in the $101 million XPRIZE Healthspan competition through its KLOTHO-UP™ study initiative.

Forward-Looking Statements

This press release contains forward-looking statements regarding investigational technologies and potential health applications. These technologies are investigational and are not approved by the U.S. Food and Drug Administration for the treatment of specific diseases unless otherwise indicated. Actual results may differ materially from those expressed or implied.

Contact: email Email Contact Web Sites: www.LionheartLongevity.com + www.LionheartHealthStim.com + www.LeonhardtVentures.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., an Orange County–based leader in regenerative health and longevity innovation, today announced it is a proud sponsor of the Anaheim Ducks, with audio and billboard advertising booked for all remaining games of the season televised on the Victory+ TV Network, a free-to-access platform available to the public.

Headquartered in Huntington Beach, Lionheart Health operates a multidisciplinary research and development laboratory in Irvine at the UCI Research Park, along with a Research Clinic Training Center and flagship treatment clinic in Newport Beach. Lionheart’s clinical programs focus on skin and hair regeneration, joint and bladder health, vision and brain health, immune optimization, sexual vitality, blood pressure, diabetes and inflammation modulation, weight loss without muscle loss, and comprehensive healthspan longevity protocols.

All Lionheart Health programs are built on a patented, clinically validated technology platform centered on precision bioelectric stimulation to modulate regenerative protein expression—supporting the body’s natural repair, resilience, and performance systems.

In addition to its clinical and research operations, Lionheart Health offers more than 200 curated health and beauty optimization products through the Lionheart Health Optimization eStore, featuring advanced devices, supplements, and wellness solutions selected to support skin, hair, metabolic, muscle, brain, immune, and longevity goals. The eStore is available online at www.LionheartHealthStim.com

Lionheart Health is a Top-40 Semi-Finalist in the XPRIZE Healthspan competition and an AbbVie Allergan ULP Innovation Award winner. The company is also a two-time Octane Finalist for Life Sciences Technology Company of the Year, a 2025 Finalist in the Orange County Business Journal Innovator of the Year Awards, and was recognized in 2025 by MedTech Outlook Magazine as Micro-Stimulator Developer of the Year.

With more than 700 issued and pending patent claims, Lionheart Health is supported by a Scientific and Clinical Advisory Board whose members collectively have authored over 6,200 peer-reviewed scientific publications. Founder Howard Leonhardt has led inventions and technologies that have treated more than 650,000 patients worldwide to date.

“Partnering with the Anaheim Ducks allows us to connect with our local community while showcasing Orange County innovation on a national stage,” said Howard Leonhardt, Founder and Executive Chairman of Lionheart Health, Inc. “We’re proud to support elite athletic performance, recovery, and long-term health through science-driven regenerative technologies.”

About Lionheart Health, Inc.
Lionheart Health, Inc. is a regenerative health, wellness, and longevity company developing and delivering patented bioelectric stimulation technologies and clinical protocols designed to enhance healthspan across muscle, brain, immune, cardiovascular, and metabolic systems. Lionheart Health operates clinics, research facilities, and licensed partner locations in the U.S. and internationally.

For more information, visit www.LionheartLongevity.com and www.LionheartHealthStim.com

Note - The Lionheart Klotho-Up Study is Investigational and requires informed patient consent to participate. This study delivers healthy fresh klotho favoring high protein and low carb and low sugar meals to your home plus personalized klotho favoring supplements and requires exercise with the BodStim TM Wiemspro Electrical Muscle Stimulation suit 2 or 3X a week for one hour (designed to get muscle and kidney tissues to secrete more klotho into circulation).

Anaheim Ducks Ad Schedule (Q1/Q2 2026)

1. Wed, Feb 25 – 7:30 PM vs Oilers

2. Fri, Feb 27 – 7:00 PM vs Jets

3. Sun, Mar 1 – 5:00 PM vs Flames

4. Tue, Mar 3 – 7:00 PM vs Avalanche

5. Wed, Mar 4 – 7:00 PM vs Islanders

6. Fri, Mar 6 – 6:00 PM vs Canadiens

7. Sun, Mar 8 – 6:00 PM vs Blues

8. Tue, Mar 10 – 5:30 PM at Jets

9. Thu, Mar 12 – 4:00 PM at Maple Leafs

10. Sat, Mar 14 – 10:00 PM at Senators

11. Sun, Mar 15 – 4:00 PM at Canadiens

12. Wed, Mar 18 – 7:00 PM vs Flyers

13. Fri, Mar 20 – 7:00 PM at Mammoth

14. Sun, Mar 22 – 5:00 PM vs Sabres

15. Tue, Mar 24 – 7:00 PM at Canucks

16. Thu, Mar 26 – 6:00 PM at Flames

17. Sat, Mar 28 – 12:30 PM at Oilers

18. Mon, Mar 30 – 7:00 PM vs Maple Leafs

19. Wed, Apr 1 – 7:00 PM at Sharks

20. Fri, Apr 3 – 7:00 PM vs Blues

21. Sat, Apr 4 – 7:00 PM vs Flames

22. Tue, Apr 7 – 7:00 PM vs Predators

23. Thu, Apr 9 – 7:00 PM vs Sharks

24. Sun, Apr 12 – 5:00 PM vs Canucks

25. Tue, Apr 14 – 5:00 PM at Wild

26. Thu, Apr 16 – 5:00 PM at Predators

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health today announced the launch of its Lionheart Health Optimization Membership Program, a science-forward, clinician-guided longevity membership designed to help individuals actively improve their healthspan using deep biomarkers, personalized protocols, and access to breakthrough clinical programs.

For $463 upfront—equivalent to just $1.27 per day—members gain immediate access to comprehensive diagnostics and personalized health planning. At year one plus one day, the ongoing annual membership renews at $365 per year, maintaining continued access to Lionheart’s optimization ecosystem.

What Members Receive

461-Biomarker Comprehensive Health Panel
An advanced diagnostic snapshot covering metabolic, cardiovascular, immune, inflammatory, hormonal, and longevity-associated pathways—forming the quantitative foundation for personalized health optimization.

Personalized Supplement Design Kit
Used to formulate a precision supplement protocol aligned to each member’s unique biology, goals, and biomarkers.

1-Hour One-on-One Functional Health Consultation
A dedicated session with a Lionheart-affiliated functional health clinician to review results, discuss goals, and map a clear path forward.

Personalized Health Optimization Protocol
A clinician-guided plan with a strong focus on elevating klotho levels, a longevity-associated protein linked in published research to muscle strength, brain function, vascular health, and immune resilience.

Member-Only Benefits & Ecosystem Access

Exclusive Discounts on 200+ Curated Products & Services
Including preferred pricing at Lionheart Longevity & Wellness licensed clinics worldwide, plus access to advanced technologies such as CoreViva™ AI-enhanced MRI, DNA testing, breathing and sleep analysis, gut and immunity health assessments, and more.

Whole-Body Health Optimization Pathways
Programs addressing:

• Muscle and metabolic health

• Brain and cognitive performance

• Sexual and hormonal health

• Joint and mobility support

• Vision and sensory health

• Blood pressure and inflammation modulation

• Weight loss without muscle loss

• Body toning, skin rejuvenation, and hair regeneration

Private Community Access
Members-only discussion groups on Facebook and WhatsApp, enabling education, peer support, clinician insights, and ongoing engagement.

Special Access: The Lionheart Klotho-Up™ Study

Members receive priority access to cutting-edge clinical research, including the Lionheart Klotho-Up™ Study, currently competing in the XPRIZE Healthspan Semi-Finals.

The Klotho-Up Study is a comprehensive, real-world healthspan intervention designed to elevate klotho levels and improve muscle, brain, and immune health. Depending on eligibility, country based regulatory approvals and clinical oversight, the program may include:

• Daily delivery of klotho-favoring, health-optimized fresh meals directly to the participant’s home

• Klotho-supportive supplement protocols personalized to DNA test and blood biomarker results

• BodStim™ EMS Suit training, utilizing specialized bioelectric signaling sequences designed to stimulate the kidneys and skeletal muscle to secrete higher levels of klotho through targeted neuromuscular activation

Additional therapeutic options are available through affiliated Lionheart Health licensed and trained clinics outside the U.S. (OUS), where regulatory pathways allow for expanded clinical offerings under physician Medical Director and DSMB supervision, IRB approval and informed patient consent.

A Measurable Path to Longer Healthspan

“Most wellness programs offer advice. Lionheart offers measurement, personalization, and access to real innovation,” said Lionheart Health leadership. “This membership is designed to be a long-term partnership—starting with deep biomarker insight and progressing toward measurable improvements in how people feel, function, and age.”

The Lionheart Health Optimization Membership Program is now open for enrollment.

Learn more, schdule a Zoom consultation or join today:
🌐 https://lionheartlongevity.com/membership/

About Lionheart Health
Lionheart Health is a regenerative medicine and longevity healthspan company focused on translating advanced diagnostics, bioelectric stimulation, and precision health protocols into measurable improvements in muscle, brain, immune, and metabolic health. Through its membership platform, eStore, licensed clinics, and clinical research programs, Lionheart aims to extend healthspan—not just lifespan.

Media Contact:
Email Contact
Lionheart Health, Inc.

www.LionheartLongevity.com

www.LionheartHealthStim.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, a regenerative health and longevity technology company, today announced a strategic partnership with Rejuvant, the developer of the patented, sustained-release Calcium alpha-ketoglutarate (CaAKG) supplementation, as part of Lionheart Health’s participation in the XPRIZE Healthspan Semi-Finals. Lionheart Health was selected as a top 40 semi-finalists out of more than 600 entries in spring 2025.

Under the collaboration, Rejuvant’s CaAKG supplement—associated with peer-reviewed research demonstrating improvements in biological age markers—has been designated a mandatory core component of the Lionheart KLOTHO-UP™ Study and the broader Lionheart Klotho Wellness Program, both of which are central to Lionheart’s XPRIZE Healthspan initiative.

A Comprehensive, Technology-Driven Healthspan Platform

The Lionheart KLOTHO-UP™ Study integrates Rejuvant’s CaAKG supplementation within a multi-modal healthspan optimization framework designed to evaluate coordinated improvements across muscle, metabolic, immune, cardiovascular, and brain health domains.

In addition to Rejuvant CaAKG, all study participants receive:

• SNiP Nutrition™ personalized supplements, customized based on genetic and biomarker profiles
• Targeted Klotho-focused supplementation
• Lionheart Health’s BodStim™ bioelectric exercise platform, delivering Klotho- and follistatin-elevating electrical muscle stimulation–enhanced exercise sessions (1 hour, 2–3 times per week)

This integrated approach reflects Lionheart’s belief that meaningful healthspan extension requires both lifestyle optimization and advanced biological technologies working in concert.

Deep, Longitudinal Measurement of Healthspan Outcomes

All enrollees in the KLOTHO-UP™ Study and Klotho Wellness Program undergo an extensive testing and evaluation protocol at baseline, 3 months, 6 months, and 12 months, including:

• 461-biomarker comprehensive blood panel including klotho levels
• AI-enhanced full-body MRI, with targeted organ and tissue analysis OPTIONAL
• Muscle health - grip strength, 6 minute walk, muscle mass index, gait speed
• Gut health, immunity strength and microbiome assessment
• Breathing and sleep analysis OPTIONAL
• Stress and inflammation profiling, including cortisol measurement OPTIONAL
• Blood sugar and metabolic regulation analysis
• Vascular and calcification assessment OPTIONAL
• Joint health and mobility evaluation OPTIONAL
• Sexual health assessment OPTIONAL
• Vision and hearing evaluation OPTIONAL
• Brain health testing, including cognition, memory, and mood metrics

This longitudinal design enables objective tracking of functional healthspan changes over time rather than reliance on single-endpoint or short-duration outcomes.

Visit > https://lionheartlongevity.com/treatment/klotho-wellness-program/ to book a consultation to learn more.

Leadership Perspectives

“Rejuvant’s CaAKG platform represents one of the most rigorously studied nutritional interventions in the biological aging space,” said a spokesperson for Lionheart Health. “By making CaAKG a mandatory core component of our XPRIZE Healthspan protocol, we are anchoring our program in validated metabolic biology while layering in advanced bioelectric, Klotho-focused, and personalized technologies.”

A representative from Rejuvant added, “We are excited to partner with Lionheart Health in the XPRIZE Healthspan Semi-Finals. This collaboration allows CaAKG supplementation to be evaluated within one of the most comprehensive, biomarker-driven healthspan programs ever assembled.”

About Lionheart Health

Lionheart Health is a regenerative health and longevity technology company developing integrated platforms focused on bioelectric control of regenerative protein expressions, Klotho-centric biology, personalized nutrition, and advanced diagnostics. Lionheart Health is an XPRIZE Healthspan Semi-Finalist, advancing multi-modal approaches designed to extend functional healthspan across muscle, immune, metabolic, cardiovascular, and brain systems. They are an Abbvie Allergan Innovation Award Winner. Finalist in 2025 Octane Life Sciences Technology Co of Year Award and Orange County Business Journal's 2025 Innovator of Year competition. Recognized by Medtech Outlook Magazine as Stimulator Developer of Year 2025. 700+ patent claims issued, pending, in process, licensed or optioned covering healthspan longevity. Clinic data on hundreds of patients. Working with OEM manufacturer suppliers multiple FDA 510K market clearances.

About Rejuvant

Rejuvant is a longevity biotechnology company developing clinically researched and patented Calcium alpha-ketoglutarate (CaAKG) supplements aimed at supporting healthy aging. Rejuvant’s formulations are informed by peer-reviewed research and are designed for integration into advanced health optimization and longevity programs.

Media Contact:
Brian Hardy
Director of Marketing
Lionheart Health
Email Contact

Phone: (424) 291-2133. Clinics AI Receptionist Number 949-710-3100

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., via Leonhardt Ventures LLC, announced the filing of a provisional patent application for a bioelectric stimulation platform designed to significantly enhance peptide uptake and biological effectiveness across oral, topical, and injectable delivery methods.

The invention addresses a persistent challenge in both biotech and longevity medicine: translating promising peptide biology into consistent, real-world outcomes. The platform is designed to improve absorption and signaling efficiency across key healthspan-related pathways, including klotho, sirtuins, sestrins, apelin, LIM, BDNF, SDF1, PDGF, VEGF, S100a, and related proteins.

Up to 70% of IV delivery is lost and up to 99.9% of oral and topical deliveries are lost with current peptide delivery methods.

Delivery Route % Lost / Filtered / Ineffective % Reaching Target Tissues (Functional) Oral 90–99.9% 0.1–10% (often <1%)Topical 80–99% 1–20% (mostly local)IV 30–70% 30–70% (systemic, uneven)

Peptides are a rapidly expanding area of research in longevity science, yet delivery and bioavailability remain limiting factors. By applying controlled bioelectric stimulation, the technology aims to enhance peptide efficacy and uptake, with early experimental data indicating improvements of up to 300 percent. This may enable lower dosing while maintaining or increasing therapeutic impact.

Lionheart Health is recognized for its leadership in klotho-based longevity research and was recently named a Top 40 semifinalist in the XPRIZE Healthspan competition. The company holds multiple issued patents related to klotho technologies, with additional applications pending.

The patent builds on decades of bioelectric medicine research conducted by Leonhardt Ventures and expands Lionheart Health’s proprietary platform for modulating cellular environments to optimize peptide and protein activity. Precisely tuned bioelectric signals are designed to enhance barrier transport, receptor interaction, and downstream tissue-level effects.

“This filing represents a major step forward in making advanced peptide-based longevity interventions more efficient, predictable, and scalable, By combining peptides with bioelectric signaling, we believe we can unlock significantly greater biological impact at lower doses, across multiple routes of administration,” stated Howard J. Leonhardt, Executive Chairman, Inventor and co-CEO of Lionheart Health, Inc. and CEO of Leonhardt Ventures LLC

Key Innovation Highlights

• Broad Delivery Coverage

Patent claims encompass oral, topical, and injectable peptide delivery enhanced by targeted bioelectric stimulation.

• Healthspan & Longevity Focus

Designed to support muscle, brain, immune, metabolic, aesthetic, cardiovascular, and regenerative health.

• Klotho-Centric Applications

Special emphasis on peptides that enhance Klotho activity, a protein closely linked to aging regulation and cellular resilience.

Mechanisms of Action (Patent-Described Concepts)

• Enhanced Transmembrane Transport

Bioelectric fields modulate membrane potential to facilitate peptide passage across epithelial and cellular membranes.

• Improved Barrier Permeability

Temporary, reversible changes to tight junction behavior in the gut and skin improve oral and topical peptide absorption.

• Receptor Sensitization

Electrical signaling increases receptor availability and responsiveness, improving peptide binding efficiency.

• Intracellular Trafficking Optimization

Bioelectric cues influence cytoskeletal dynamics and endosomal pathways to reduce peptide degradation and increase functional delivery.

• Dose Efficiency Amplification

Enhanced uptake allows for lower peptide doses while maintaining or increasing biological effects.

• Synergistic Klotho Signaling

Electrical stimulation is designed to favor cellular environments that amplify Klotho-related pathways tied to longevity and tissue protection.

Potential Strategic Impact

The newly filed intellectual property strengthens Lionheart Health’s position at the intersection of bioelectric medicine and peptide therapeutics, creating opportunities for:

• Next-generation longevity and wellness protocols

• Licensed clinical and research applications

• Integration into future Lionheart Health devices, programs, and clinical studies

New studies include a combination of bioelectric stimulation enhanced peptides (klotho) with PEMF, electromagnetic high intensity RF, LED light, vibrational therapy, sauna, cold plunge, hyperbaric oxygen, BodStim TM enhanced exercise, healthy klotho-favoring diet, and customized supplements including pre and pro biotics.

The company plans to incorporate the technology into selected upcoming healthspan initiatives and investigational protocols, while pursuing strategic partnerships and licensing opportunities.

About Lionheart Health

Lionheart Health is a longevity and regenerative medicine company focused on advanced bioelectric protein expression technologies, peptide science, stem cell compositions, nutrient hydrogel, delivery systems, and next-generation healthspan longevity and medical aesthetics solutions. Spun out of Leonhardt Ventures LLC in 2022.

About Leonhardt Ventures LLC

Leonhardt Ventures LLC is an innovation venture studio founded in 1982 to develop and commercialize breakthrough technologies in bioelectric medicine, regenerative science, and human longevity.

Media Contact:

Lionheart Health

Email: Email Contact

Websites:

http://www.lionhearthealthstim.com

http://www.LionheartLongevity.com

http://www.LeonhardtVentures.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., a leader in bioelectric regeneration and longevity biotechnology, today announced the filing of a groundbreaking non-provisional U.S. patent covering its new platform technology: Bioelectric-Enhanced Klotho Nanoflowers for Aging Reversal and Healthspan Extension.

The newly filed patent protects a transformative therapeutic system that combines nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target the cellular and mitochondrial drivers of aging. The invention integrates several proprietary Lionheart technologies, including BodStim™, BrainBand™, HairCell™, ErectiStim TM, Second Brain TM, InStim TM, EyeCell TM, EarCell TM, BioLeonhardt TM, KidneyCell TM, LiverCell TM, RegenaLung TM, Pantropelstin creaCell TM, TestiStim™, ErectiStim™, and advanced Klotho-based peptides and gene-expression tools.

A Novel Approach to Reversing Cellular Aging

The patented platform centers on engineered “nanoflowers”—flower-shaped hybrid nanoparticles capable of:

• Upregulating Klotho, a longevity-associated protein shown to improve brain, kidney, cardiovascular, and metabolic health
• Restoring mitochondrial function by enhancing ATP production and reducing oxidative stress
• Delivering targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators
• Acting as nanozyme catalysts that reduce ROS and improve cellular resilience
• Enhancing regenerative signaling when activated by precise bioelectric patterns

The nanoflowers are engineered to respond to Lionheart’s proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance.

This invention represents the convergence of three of the most powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation,” said Howard J. Leonhardt, Founder, Lead Inventor and Chief Executive Officer of Lionheart Health. “Our goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably.

Nanoflowers & Bioelectric Stimulation Are Synergistic

The nanoflowers are specifically engineered to respond to bioelectric fields.
The bioelectric signals increase:

• cellular uptake of nanoflowers,

• intracellular transport, and

• activation of the nanoflower’s catalytic and genetic payloads.

Thus, nanoflowers require bioelectric activation for optimal performance, and the bioelectric component is designed to operate in the presence of the nanoflowers.

Bioelectric stimulation is applied to:

• open ion channels,

• improve endocytosis,

• direct nanoflowers toward mitochondria, and

• trigger therapeutic payload release.

Klotho Upregulation Is a Combined Output of Both Components

Klotho expression increases due to:

• nanoflower-delivered genetic or peptide payloads, and

• bioelectric activation of promoter and epigenetic pathways.

Thus, neither nanoflowers nor bioelectric stimulation alone can produce the full Klotho-enhancing effect, demonstrating a combined therapeutic benefit mechanism.

Designed for:

SYSTEM-WIDE HEALTHSPAN IMPROVEMENT

Mitochondrial Biogenesis

Activation of PGC-1α, NRF1/2, TFAM, leading to new mitochondrial formation.

Reduction of Cellular Senescence

Lower oxidative stress reduces p16/p21 pathways and senescence-associated β-gal.

Stabilization of Biological Age

Combined mitochondrial repair + Klotho enhancement reduces multi-system aging markers.

Inspired by the Future of Regenerative Medicine

Klotho is widely recognized as one of the most promising longevity molecules ever discovered. Decreased Klotho levels are associated with accelerated aging, cognitive decline, inflammation, vascular calcification, kidney dysfunction, and frailty. Increasing Klotho expression has demonstrated benefits in preclinical models of brain aging, muscle repair, cardiac healing, kidney protection, and metabolic health.

Lionheart’s new platform advances this science by enabling targeted Klotho delivery and activation inside mitochondrial and cellular compartments that are most responsible for aging.

“Bioelectric-enhanced Klotho nanoflowers give us a programmable, multi-modal tool to address the root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity,” said Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation. “This filing marks a major milestone in longevity therapeutics.”

Positioning Lionheart as a Global Leader in Healthspan Technologies

The patent filing adds to Lionheart Health’s growing intellectual property portfolio spanning:

• Bioelectric-controlled protein expression including klotho, sestrins, sirtuins, NANOG, apelin, SDF1, PDGF, LIM, S100a, Tropelastin, COL17A1, VEGF and more.
• Stem-cell mobilization and tissue regeneration
• Mitochondrial restoration technologies
• Klotho-based gene therapy and peptide therapeutics
• Regenerative aesthetic and wellness platforms

OPTIONAL COMPONENTS include:

Closed-Loop Adaptive Control

Sensors measure mitochondrial markers or electrophysiological signals to adapt stimulation patterns.

Multi-Modal Integration

Nanoflowers + bioelectric + peptides + red light + PEMF + regenerative support including cell and gene therapy.

Repeat Cycle Integration

Therapy will be delivered in studies in iterative sessions (baseline, 3-month, 6-month, 12-month intervals).

Lionheart Health is currently preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics across the U.S. and outside of the USA. Company plans to integrate bioelectric-enhanced Klotho nanoflowers into its XPRIZE Healthspan competition program.

About Lionheart Health, Inc.

Lionheart Health, Inc. is pioneering a new era of bioelectric, regenerative, and longevity technologies. The company develops clinically validated systems for organ repair, cellular rejuvenation, hair regeneration, muscle restoration, metabolic optimization, and age reversal. Its mission is to extend healthspan and improve quality of life for people worldwide through safe, non-invasive, high-impact technologies.

Learn more at:

www.LionheartHealthStim.com

www.LionheartLongevity.com

www.LeonhardtVentures.com

Media Contact:

Lionheart Health Communications & Customer Service

Email: Email Contact

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

The inaugural Klotho Conference & Scientific Seminar, held September 15–16 at the UCI Beall Applied Innovation Center, brought together leading researchers, clinicians, and innovators to discuss the most recent Klotho biology research, its therapeutic potential, and diagnostic advances. This landmark event marked a significant step forward in translating decades of Klotho research into actionable strategies for healthspan extension.

Short highlight reel > https://youtu.be/ngH6qERXwRI

Playlist of ALL Klotho Conference Presentations in full link is here > https://www.youtube.com/playlist?list=PLIzjBuzofFehaUfXU0GdvI2X8cr3gm6SY

Key Highlights from the Conference

• State of the Industry & Foundational Science
  The conference opened with a “State of the Industry” address by Menachem Abraham, followed by a keynote from Dr. Makoto Kuroo, who discovered the Klotho gene. Their talks framed the current landscape of Klotho research, from molecular pathways to clinical translation. Klotho Conference

• New Klotho therapeutic modalities 

Carmela Abraham presented results of a Klotho-mRNA-LNP approach to increasing Klotho levels. Klotho Conference

• Human Case Studies & Clinical Insights
  Petr Sramek presented compelling human case studies exploring Klotho-based therapies, shedding light on the translational journey from preclinical models to patient outcomes. Klotho Conference

• Klotho and Brain Health
  A dedicated panel, led by Dr. Dena Dubal and Dr. Miguel Chillon, examined emerging evidence for Klotho’s neuroprotective role including its impact on neurodegenerative disease models and its potential for gene therapy applications. Klotho Conference

• Klotho and cancer
  Dr. Ido Wolf and Dr. Tamar Rubinek summarized their research on the potential of Klotho in malignant tumors suppression.

Klotho Conference

• Gene Therapy for Longevity Diseases
  Dr. Assumpció Bosch delivered a presentation on Klotho gene therapy for ALS, outlining preclinical progress and the roadmap for future clinical trials. Klotho Conference

• Inflammation, Aging & Klotho
  Inflammation-focused research was a major topic: Dr. Iliya Lefterov and Dr. Radosveta Koldamova discussed how Klotho signaling intersects with inflammatory pathways and its implications for chronic disease and aging. Klotho Conference

• Muscle, Movement & Regeneration
  A panel including Dr. Mona EzzatVilinov and celebrity fitness expert Ramona Braganza explored Klotho’s role in muscle regeneration, functional mobility, and exercise-driven healthspan. Klotho Conference+1

• Aesthetics & Regenerative Medicine Applications
  Dr. Gail Humble discussed cutting-edge research into Klotho’s use in medical aesthetics — covering skin, hair, and tissue regeneration. Klotho Conference

• Klotho in Organ Regeneration
  Dr. Doris Taylor closed out major talks with her visionary presentation on Klotho’s regenerative applications for organs and cardiovascular tissue. Klotho Conference

• From Bench to Bedside
  Dr. Ian White delivered a keynote outlining the translational path for Klotho therapies, including how naturally derived human Klotho sources can move into clinical trial phases. Klotho Conference

• Thought Leadership on Healthspan
  Dr. Joseph Cleaver gave a luncheon keynote on lifestyle, aging, and Klotho — synthesizing scientific insight with practical takehome messages for wellness practitioners. Klotho Conference

Short summary of klotho research:

• 4390 papers have been published on klotho since 1997.
• Clear conclusion if you are low in circulating klotho you are likely aging more rapdily than you should.
• Low klotho seems to increase cancer risk.
• Low klotho leads to earlier decline in cognition and memory and higher liklihood of brain disorders.
• Low klotho leads to higher risk of heart failure and kidney failure.
• Low klotho precipitates higher levels of calcification and inflammation.
• Low klotho leads to muscle atrophy and sarcopenia.
• Low klotho may contibute to depression, anxiety and addictions.
• Low klotho inihibits sexual health.
• Low klotho is a major underlying cause of joint osteoarthritis.
• Low klotho increases liklihood of epileptic seizures in those under 65.
• Low klotho leads to earlier aging related hair loss.
• Low klotho leads to higher levels of skin damage and wrinkles.
• Low klotho leads to earlier age related vision deterioration.
• Low klotho leads to earlier age related hearing loss.
• Low klotho leads to higher risk of osteoporosis and other bone strength loss disorders.
• Low klotho leads to higher oxidative stress.
• Low klotho leads mitochondrial dysfunction.
• Low klotho leads to higher susceptibility to infections.
• Low klotho leads to slower wound healing.
• Low klotho leads to accelerated telomere shortening and epigenetic age acceleration.
• Low klotho reduces healthspan and longevity.
• Studies are underway to prove out that higher klotho levels can reverse the above low klotho findings.

Conference Impact and Outcomes

• Attendees engaged in interactive Q&A sessions and roundtables to build collaborative pathways for Klotho research and commercialization.

• Several research groups indicated plans to accelerate clinical development of Klotho-based gene therapies.

• The conference catalyzed new partnerships, including academic institutions, biotech companies, and longevity-focused investor networks.

• It reinforced the unified mission: raising Klotho biology into mainstream medical and therapeutic strategy to promote healthy aging.

Looking Forward

The success of this first Klotho Conference sets the stage for annual gatherings to follow. Organizers announced that future conferences will expand to include translational clinical trials, diagnostics development, and policy frameworks to bring Klotho therapies to patients responsibly and equitably.

About Klotho Conference & Scientific Seminar

The Klotho Conference is a dedicated forum for exploring the science and therapeutic potential of the Klotho protein and gene. Hosted at UCI’s Beall Applied Innovation Center, this event brings together top-tier academics, clinicians, and innovators to accelerate healing and longevity through Klotho research. Klotho Conference

Media Contact:
Klotho Conference Organizing Team
Email: Email Contact

Website: www.klothoconference.com Klotho Conference

Primary Sponsor:
Lionheart Health, Inc., 21010 Pacific City Cir #1406, Huntington Beach, CA 92648

Web Sites: www.lionheartlongevity.com |  www.lionhearthealthstim.com |  www.leonhardtventures.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Leonhardt Ventures LLC today announced a major leap forward in regenerative medical technology with the introduction of E-Stent™, the first wireless, bioelectric protein-expression stent designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues.

Developed by the Leonhardt R&D engineering team in Irvine, led by CTO Brian Lasater and CEO Howard Leonhardt, the E-Stent™ system combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions (bioelectric signals) to micro-coils embedded along the stent. Stent sizes range from micro-implants smaller than a pea to 28 mm aortic stents, enabling applications across multiple organ systems.

"This is no longer a theory or a dream we have working prototypes in testing now which are controlling regenerative and healing protein expressions on demand enabled fully by wireless energy" stated Brian Lasater CTO of Leonhardt Ventures LLC and Lionheart Health, Inc.

Exclusive Licensing Across 29 Specialized Applications

Leonhardt Ventures LLC has granted exclusive licenses for the E-Stent™ platform to the following entities:

1. KidneyCell™ http://www.kidney-cell.com- for kidney regeneration
2. CerebraCell™ http://www.cerebracell.com- for brain health, stroke and TBI recovery, brain aneurysm treatment
3. AddictiStim™ http://www.addictistim.com- for addiction treatment
4. MemoryStim™ http://www.memory-stim.com- for memory improvement, dementia, and Alzheimer's treatment
5. DepressiStim™ http://www.depressistim.com- for severe depression and anxiety treatment
6. BioLeonhardt™ http://www.bioleonhardt.com- for heart regeneration
7. CancerCell™ http://www.cancercellinc.com- for cancer treatment
8. Ear-Cell™ http://www.ear-cell.com- for hearing regeneration
9. Eye-Cell™ http://www.eye-cell.com- for vision regeneration
10. Lionheart Health http://www.lionhearthealthstim.com- for healthspan longevity and medical aesthetics
11. Vascustim™ http://www.vascustim.com- for limb salvage, leg and foot wound healing, peripheral artery disease
12. AortaCell™ http://www.aortacell.com- for aorta regeneration, aortic aneurysm treatment
13. SpineStim™ http://www.spine-stim.com- for spinal cord injury recovery
14. BioPace™ http://www.bio-pace.com- for biological pacemaker regeneration
15. PressureStim™ http://www.pressurestim.com- for blood pressure control
16. InStim™ http://www.instimcell.com- for inflammation modulation and bowel or digestion disorders
17. LiverCell™ http://www.livercellstim.com- for liver regeneration
18. BladderCell™ http://www.bladdercell.com-for bladder dysfunction recovery
19. BreatheStim™ http://www.breathestim.com- for breathing and sleep optimization
20. ImplantStim™ http://www.implantstim.com- for dental implant healing
21. Second Brain™ http://www.secondbrainstim.com- for gut health optimization
22. Stem Cell Bra™ http://www.stemcellbra.com- for breast augmentation
23. SkinStim™ http://www.skin-stim.com- for skin regeneration
24. ErectiStim™ http://www.erectistim.comand FemStim™ - for sexual health
25. TestiStim™ http://www.testistim.com- for testosterone management
26. TremorStim™ http://www.tremorstim.com- for essential tremor treatment
27. PancreaCell™ https://vimeo.com/170533425?fl=pl&fe=sh- for pancreas regeneration and diabetes treatment
28. OrthoStim™ http://www.ortho-stim.com- for all orthopedic applications, including knee osteoarthritis, hip healing, and bone density
29. DentaCell™ http://www.dentacellaccelerator.com- for all dental applications

A New Frontier in Regenerative Medicine

Through selective bioelectric signaling, th E-Stent™ platform can stimulate or inhibit a broad range of proteins, including klotho, sestrins, sirtuins, apelin, LIM, CXCL5, tropoelastin, COL17A1, SDF1 (stem cell homing), PDGF, NANOG, RANK-L, BMP9, OPG, VEGF, S100a, HIF1a, BDNF, Sonic Hedgehog, TGFb, and FABp4 downregulation, and many others known to influence.

These stimulations can be directed to control stem cell homing, proliferation, and differentiation on demand, improving circulation, restoring muscle strength, modulating inflammation and blood pressure, improving nerve connections and viability, restoring elasticity, and more.

This platform represents a significant evolution of Leonhardt Ventures' previously announced KlothoImplant Bioelectric MicroImplant for controlling protein expressions on demand, KLOTHO, expanding the same core capabilities into advanced vascular implant formats.

The Lionheart Health (majority owned by Leonhardt Ventures LLC) team was recently recognized by Medtech Outlook Magazine as Micro Implant Stimulator Development of the Year 2025 https://www.medicaltechoutlook.com/lionheart-health-inc

Lionhert Health was also recently recognized as Abbvie Allergan ULP Innovation of the Year in Medical Aesthetics and as a top 40 semi-finalist in the $101 Million Xprize Healthspan competition out of 600 entries. Other recent distinctions include a 2025 finalist in both OCBJ Innovator of the Year and Octane Life Sciences Technology Co of the Year Awards.

For more information or interview requests, please email:  Email Contact

About Leonhardt Ventures LLC

Leonhardt Ventures www.leonhardtventure.com and its affiliated teams have been developing medical technologies since 1982. More than 600,000 patients worldwide have been treated with Leonhardt's inventions to date.

About Lionheart Health, Inc.

Lionheart Health is a 2022 spin out of Leonhardt Ventures LLC focused on the convergence of healthspan longevity and medical aesthetics - aging reversal inside and out. Primary business model is licensing clinics it's proprietary technology platform harnessing bioelectric stimulation to control regenerative protein expressions. The flagship development of this team is a whole body regeneation chamber "a womb for adults". They are recognied as the world leader in elevating circlating klotho levels, a tool for aging reversal and healthspan longevity, currently enrolling in clinical studies worldwide.

Leonhardt Ventures LLC

Office Headquarters

210101 Pacific City Cir 1406
Huntington Beach, CA 92648

R&D Lab

5270 California Avenue
Irvine, CA 92617

Lionheart Health, Inc.  |  Leonhardt Ventures LLC

Research Clinic and Training Center

4740 Von Karman, Ste 150
Newport Beach, CA 92660

http://www.leonhardtventures.com

http://www.lionhearthealthstim.com

http://www.lionheartlongevity.com

Disclaimer: Products are not fully proven yet to be safe or effective all are still in clinical studies.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc. operating Lionheart Longevity & Wellness Clinics, a company focused on organ regeneration, medical aesthetics and healthspan longevity technologies, today announced it will be presenting at the 2025 The Science of Longevity themed Octane Medical Innovation Forum October 28th and 29th, 2025 in Irvine, California.

The Octane Medical Innovation Forum brings together industry experts, entrepreneurs, investors and thought leaders for two days of learning, networking and innovation on the latest insights and trends in the medical industry. For more information, visit the event website here https://www.octane-oc.org/event/omif/agenda

Howard Leonhardt, Executive Chairman & co-Chief Executive Officer of Lionheart Health, Inc., will present the latest developments of their technology platform focused on regenerative aesthetics and healthspan longevity.

The Company’s first-in-class technology platform utilizes precise patented bioelectric signaling sequences to cause release of regeneration promoting proteins upon demand. These include controlled expression of klotho a protein identified to be a key part of aging management. One patented signaling sequence controls stem cell recruitment, proliferation and differentiation on demand.

Lionheart Health's business model is to license and support thriving clinics worldwide with its's patented technology platform in exclusive territories. They have one clinic in Newport Beach, CA and 7 other licensed locations with many more licensed sites in the works. Their goal is to have 124 licensed locations up and running within the next 60 months.

The company was named earlier this year a top 40 semi-finalist in the XPRIZE Healthspan Competition out of 600 entries. This competition is focused on improvements in muscle health, brain health and immunity health with an eye goal on increasing healthy living years by 20 years. They are now working to make it to the next stage as a top 10 finalist. Earlier this month they won recognition from Medtech Outlook Magazine at the Top Micro Stimulator Implant Development of 2025 and were a finalist in the Orange County Business Journal's Innovator of the Year Award. Now this month they are a finalist in the Octane High Tech Awards in the Medical Innovation category with the awards ceremony set to be held the week September 25th. In December 2023 they won the coveted Abbvie Allergan ULP Golden Passport Award recognizing innovation in medical aesthetics.

The grandest project of Lionheart Health under development is a whole body regeneration chamber, womb for adults. The company is building an testing prototypes now with intent to release first a version utilizing only non-invasive technologies and then to follow later with a version that uses advance robotics, AI and implantable pump and stimulation technologies to regenerate internal organs. The latter is being developed with expert partners in each discipline.

Last month the company announced a special partnership with CoreViva based in Orange County for AI enhanced MRI for diagnostics. The company has been a long standing lab resident of University Lab Partners and the UCI Beall Applied Innovation Center Prototyping Lab in Irvine and has won multiple UCI Capstone Grants over the years including one for Brain Band TM its bioelectric stimulation technology platform for brain health.

About Lionheart Health

Lionheart Health, Inc. is a 2022 spin out of Leonhardt Ventures LLC formed in 1982 focused on healthspan longevity and regenerative aesthetics. Leonhardt inventions have treated more than 600,000 patients to date.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Lionheart Health, Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere our private placement memorandum . Forward-looking statements speak only as of the date of the document in which they are contained and Lionheart Health, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Contact Information:

Brian Hardy
Email Contact
Lionheart Health, Inc.
Leonhardt Ventures LLC

Research Clinic & Training Center

4740 Von Karman, Ste 150
Newport Beach, CA 92660
http://www.leonhardtventures.com
http://www.lionhearthealthstim.com
http://www.lionheartlongevity.com

R&D Lab

5270 California Avenue
Irvine, CA 92617

Office Headquarters

21010 Pacific City Cir #1406
Huntington Beach, CA 9248

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc. has announced a special partnership with CoreViva to offer AI enhanced full body MRI to its Lionheart Klotho Wellness Program patients. CoreViva provides arguably the most advanced full body MRI scans with an FDA-cleared AI.

Lionheart Health is a semi-finalist (final 40 out of 600 entries) in the $101 million Xprize Healthspan competition with a protocol focused on elevating circulating klotho levels. The core of this protocol is…

1. Klotho promoting meals home delivered.
2. Daily klotho supplements including gut health, brain health, muscle health and immunity boosting supplements.
3. BodStim TM bioelectric klotho enhanced exercise.

In addition to the above core mandatory items participants may also optionally receive hyperbaric oxygen, red light, infrared sauna, ozone, PEMF, muscle toning, sexual health, joint health, brain health, skin health, breathing health, sleep health, stress management, inflammation and blood pressure reduction, gut health, nature therapy, vision and hearing health therapies.

"Launching our patients into the Lionheart Klotho Wellness Program with the CoreViva advanced AI analysis whole body MRI will give us a great baseline on their current health status, and we will run through again at 12 months. We are out to prove in our studies improvement of muscle health, cardiovascular health including calcification reduction, immunity health and brain health and this AI MRI will help us track progress," stated Dr. Leslie Miller Chief Medical Officer for Lionheart Health, Inc.

About Lionheart Health

Lionheart Health, Inc. is a 2022 spin out of Leonhardt Ventures LLC www.LeonhardtVentures.com that has been developing breakthrough medical innovations since the early 1980’s. The core team regenerated their first organ in 1988. Lionheart Health is focused on applying Leonhardt patented inventions in bioelectric protein expressions to medical aesthetics and healthspan longevity www.LionheartHealthStim.com Lionheart Health's primary business model is licensing https://lionheartlongevity.com/licensing/ and supporting existing thriving clinics in exclusive territories. Over 600,000 patients have been treated with Leonhardt inventions to date.

About CoreViva

Our mission is to improve the early detection and treatment of diseases through the best whole-body MRI, wellness education, and a phenomenal patient experience https://coreviva.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Orange County, CA August 21, 2025 Lionheart Health, Inc., an innovation leader in the development of products for healthspan longevity and medical aesthetics is proud to announce its recognition as a finalist in the category of Best Innovation in Medical Technology Life Sciences in the prestigious High Tech Awards (HTA) organized by Octane, Orange County, CA. Octane, a pivotal connector in the innovation ecosystem, is renowned for fostering relationships, capital growth, and building community. This recognition under the innovation in life science category underscores Lionheart Health’s unwavering commitment to driving breakthrough healthspan innovations and creating impactful solutions that benefit humankind.

The flagship development of Lionheart Health is a whole body regeneration chamber, a “womb for adults” designed to extend healthspan longevity by 20 years. Powered by AI and precise robotics, the multi-modality device is driven by bioelectrically-controlled and enhanced biologics intended to regenerate organs in the human body, including hearts, kidneys, brains, livers, pancreas, lungs, skin, eyes, hearing, bladders, muscles, immune systems, and blood circulation.

Lionheart Health, Inc.’s primary business model is the licensing of its patented technology platform to qualified clinics around the world. Working with OEM manufacturing partners including Mettler Electronics of Anaheim, California (in business in Orange County since 1957) the team has landed FDA 510K market clearances for using targeted bioelectric stimulation to improve circulation, build and recover muscle strength, reduce pain and inflammation, treat arthritis including joint osteoarthritis, prevent blood clots, enhance the health benefits of exercise and improve stroke recovery. These indications of use are integrated into products for improving skin and hair health, sexual health vitality, joint pain recovery in the knee and other joints, rapid body toning and weight loss without muscle loss, and chronic inflammation reduction.

"We are honored to be recognized as a finalist at Octane’s High-Tech Awards," said Howard Leonhardt, Executive Chairman and Co-CEO. This acknowledgment is a testament to our dedication to advancing longevity and healthspan through innovation and our commitment to making a positive impact on the communities we serve. We are proud to contribute to Orange County's reputation as a significant hub for disruptive healthcare innovation in the World.”

Lionheart Health’s world headquarters is in Huntington Beach, California, and with Leonhardt Ventures LLC, they have an R&D Lab in Irvine at UCI Research Park and a Research Clinic and Training Center in Newport Beach near the John Wayne Airport http://www.LionheartLongevity.com.Lionheart Health recently won the AbbVie Allergan ULP Innovation in Medical Aesthetics Award, Medtech Outlook Stimulator Development of the Year 2025 Award, and is one of 40 semi-finalists in the $101 million XPRIZE Healthspan Competition. Lionheart Health was also announced as a finalist this past week for the Orange County Business Journal Innovator of the Year 2025 Award.

Octane 2025 Technology Awards Ceremony Thursday September 25th, 2025 in Irvine Registration Link > https://www.octane-oc.org/event/e891a457-c212-43fa-9c31-c35a57002cd9/2025-finalists

Lionheart Health is sponsoring The Klotho Conference in Irvine September 15th and 16th, 2025 Visit www.klothoconference.com to register and learn how elevating your klotho levels may increase your healthspan. If you are low in circulating klotho you likely are aging more rapidly than you should. Learn where you stand by ordering a klotho test at www.KlothoYears.com Exercising with the patented Lionheart Health BodStim TM EMS suit has demonstrated an ability to increase circulating klotho levels substantially higher than ordinary exercise. Visit to www.bodstim.com to learn more.

About Lionheart Health:

Lionheart Health is a regenerative health company dedicated to helping people lead healthier, longer lives through its advanced bioelectric and biologics technologies. With a focus on teaching the body to renew and restore itself, Lionheart Health offers FDA-cleared products for hair regeneration, sexual health, joint pain, and rapid body toning. The company's flagship clinic and training center are in Newport Beach, CA. Headquartered in Huntington Beach, Lionheart Health, with its parent company Leonhardt Ventures LLC, has an R&D Lab in Irvine at UCI Research Park and a Research Clinic and Training Center in Newport Beach.

Media Contact:

Howard J. Leonhardt
Executive Chairman & CEO
Lionheart Health, Inc.
Leonhardt Ventures LLC
4740 Von Karman, Ste 150
Newport Beach, CA 92660

Email: Email Contact
Phone: (424) 291-2133

https://www.leonhardtventures.com

https://www.lionheartlongevity.com

https://www.lionhearthealthstim.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., a leading biotech and medical device company focused on healthspan, longevity, and organ regeneration, has been recognized by MedTech Outlook as the Top Implantable Stimulator Developer of the Year.

This prestigious award underscores Lionheart Health’s breakthrough work with its patented KlothoImplant™ and MicroImplant™ stimulator technologies. These advanced devices deliver precise bioelectric signaling sequences designed to control regenerative protein expression on demand. Such proteins play a critical role in homing stem cells to target organs, building new muscle, stimulating blood vessel growth, reducing inflammation, and limiting calcification.

"This micro implant stimulator is able to control stem cell homing, proliferation and differentiation on demand and can release proteins to reverse aging, build muscle, grow new blood vessels and fight chronic inflammation" stated Brian Lasater Chief Technology Officer at Leonhardt Ventures LLC and Lionheart Health, Inc.

Working in collaboration with Leonhardt Ventures LLC, Lionheart Health has patented, developed, and tested its bioelectric stimulation platform for a wide range of applications, including regeneration of internal organs such as the heart, bladder, kidneys, pancreas, liver, brain, eyes, lungs, and gastrointestinal system. Additional applications include blood pressure modulation and hearing restoration.

The company, together with OEM manufacturing partners, has developed a full suite of devices: from clinically validated benchtop stimulators and portable handheld units, to miniaturized implantable stimulators the size of a quarter, and now micro-stimulators as small as a pea. The recognition underscores the progress made in developing implantable stimulators that have successfully passed rigorous testing, including applications for total heart and kidney regeneration.

MedTech Outlook, a leading industry publication, tracks and reports on innovative MedTech trends and solutions that drive meaningful impact for healthcare providers and patients. The publication serves as a vital link between emerging medical technologies, healthcare providers, facilities, and institutions.

Regarding this award, Brian Lasater, CTO of Lionheart Health, Inc. stated,

“Our entire team is honored to be recognized by MedTech Outlook as the Top Implantable Stimulator Developer of 2025. Being acknowledged among the most impactful innovations of the year is truly gratifying.

Lionheart Health has built a strong intellectual property foundation, with more than 500 issued and pending patent claims, multiple FDA 510(k) market clearances, and additional 510(k) applications in process in collaboration with our OEM manufacturing partners. We have developed a comprehensive portfolio of stimulators capable of delivering our patented bioelectric protein expression signaling sequences, which prompt muscle and other target tissues to release specific regenerative proteins on demand.

These proteins include SDF-1 and PDGF for stem cell homing, VEGF and eNOS for improved circulation, a broad range of anti-inflammatory proteins, and key factors for muscle building such as klotho, S100a, and follistatin. Perhaps most exciting is our progress in extending healthspan and longevity through bioelectric signaling aimed at enhancing brain, immune, and muscle health.

Additionally, Lionheart Health was recently named one of the Top 40 semifinalists in the XPRIZE Healthspan competition and continues to advance toward the $81 million grand prize.

”See www.LionheartLongevity.com + www.lionhearthealthstim.com and www.LeonhardtVentures.com for more information.

About Lionheart Health, Inc.:

Lionheart Health, Inc. is a 2022 spinout of Leonhardt Ventures LLC that has been developing breakthrough medical innovations since 2022 which is focused on healthspan longevity and medical aesthetics. The Lionheart primary business model is to license existing clinics its IP platform and provide equipment, training and support for these clinics to offer this technology platform to their patients and clients. Over 600,000 patients have been treated with Leonhardt inventions to date which generated for their licensees and acquirers close to $2 billion in annual revenues in 2024.

Corporate Contact:

Howard J. Leonhardt

Executive Chairman & CEO

Lionheart Health, Inc.

Leonhardt Ventures LLC

Research Clinic & Training Center

4740 Von Karman, Ste 150

Newport Beach, CA 92660

http://www.leonhardtventures.com

http://www.lionhearthealthstim.com

http://www.lionheartlongevity.com

R&D Lab

5270 California Avenue

Irvine, CA 92617

Headquarters

21040 Pacific City Cir #1406

Huntington Beach, CA 92648

email: Email Contact

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, a leader in regenerative health, has been nominated for the Orange County Business Journal's eleventh annual "Innovator of the Year" Awards. This prestigious recognition celebrates individuals and organizations in Orange County demonstrating exceptional brilliance and leadership in innovation.

Lionheart Health is at the forefront of extending healthy lifespans through its groundbreaking bioelectric and biologics technology. The company's innovative platform focuses on teaching the body to renew and restore itself, moving beyond symptom treatment to address the root causes of aging and decline.

"This nomination is a testament to the innovative efforts our entire Lionheart Health team has poured into developing our bioelectric and biologic technology platform for regenerative aesthetics and for increasing longevity and healthspan," said Howard J. Leonhardt, Executive Chairman and CEO.

Pioneering Regenerative Solutions

Lionheart Health's commitment to innovation is evident in its suite of FDA-cleared products. Backed by rigorous clinical studies, these solutions are currently available globally through licensed clinics and address key areas of health and wellness, including skin regeneration, hair regeneration, sexual health, joint pain relief, and rapid body toning for weight loss without muscle loss. The company's flagship research clinic, training center, and MedSpa are conveniently located in Newport Beach, California.

A Legacy of Longevity and Innovation

Lionheart Health's dedication to extending healthy life is deeply rooted in the four-decade legacy of its parent company, Leonhardt Ventures. This long-standing commitment to longevity and regeneration has driven every treatment, therapy, and advancement.

Further solidifying its innovative standing, Lionheart Health was recently named one of 40 semi-finalists out of 600 competitors in the $101 million XPRIZE Healthspan competition. This global challenge aims to demonstrate the ability to extend healthy life by 20 years, a mission that perfectly aligns with Lionheart Health's core objectives.

About Lionheart Health:

Lionheart Health is a regenerative health company dedicated to helping people lead healthier, longer lives through its advanced bioelectric and biologics technology. With a focus on teaching the body to renew and restore itself, Lionheart Health offers FDA-cleared products for hair regeneration, sexual health, joint pain, and rapid body toning. The company's flagship clinic and training center are located in Newport Beach, CA.

Howard J. Leonhardt
Executive Chairman & CEO
Lionheart Health, Inc.
Leonhardt Ventures LLC
Research Clinic
4740 Von Karman, Ste 150
Newport Beach, CA 92660

www.leonhardtventures.com

www.lionheartlongevity.com

www.lionhearthealthstim.com

Email Email Contact

R&D Lab - 5270 California Avenue, Irvine, California

Office Headquarters - 21040 Pacific City Cir Suite 1406, Huntington Beach, CA 92648

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc., an Orange County, California-based biotechnology company, has been named one of the 40 semi-finalists advancing in the $101M XPRIZE Healthspan Competition at the Longevity Investors Summit in New York City. The mission of XPRIZE is to inspire and empower humanity to achieve breakthroughs that accelerate an abundant and equitable future for all. Lionheart Health has been awarded $250,000 as part of the semi-finalist selection.

596 teams from 53 countries entered the competition. The winning team must demonstrate that their treatment restores muscle, cognitive, and immune function by a minimum of 10 years, with a goal of 20 years, in persons aged 50-80. The treatment must take 1 year or less.

Lionheart Health, Inc. has patented, developed, and is working to commercialize a technology platform that utilizes precise bioelectric signaling sequences to control release or regeneration-promoting proteins from tissues and cells. It has also developed bioelectrically enhanced biologics, including Klotho-expressing stem cells suspended in a proprietary nutrient hydrogel.

Recent studies by Abraham (2022)¹ and Dubnov (2024)² demonstrate that the Klotho protein plays a significant role in aging and longevity. It has been shown to extend lifespan and improve cognitive function in animal models, including mice and nonhuman primates. Research suggests that increasing Klotho levels through genetic manipulation, exercise, or other means may increase longevity and better overall health.

“Our solution harnesses the body's natural healing processes to promote regeneration and renewal,” stated Dr. Leslie Miller, Lionheart Health's Chief Medical Officer.

"Lionheart Health demonstrated its ability to control regenerative protein expressions at its Research and Development Lab in Irvine, California at UCI Cove, in animal studies, and in over 300 patients in pilot clinical studies to earn a spot in the final 40," stated Dr. Jorge Genovese, Vice President of Bioelectric Regeneration Research. He and Lionheart Health founder Howard Leonhardt have been working as a team on bioelectric and stem cell-based regeneration research for more than 25 years to reach this milestone.

In the next phase, Lionheart Health must demonstrate its healthspan extension protocol in an IRB-approved and data safety monitoring board-supervised one-year clinical study with patient consent.

“Advancing as an XPRIZE Healthspan top 40 finalist is a proud moment for Lionheart Health and our entire team,” says Howard Leonhardt, Lead Inventor of the Lionheart Health technology platform and Founder, Executive Chairman, and co-CEO. “Our participation in XPRIZE has already been advantageous and has accelerated our path to commercialization. We look forward to this next step, which will allow us to demonstrate our technology in a well-designed clinical trial that we believe may lead to extending healthy aging for people worldwide.

Long-term Lionheart Health, Inc. is working in partnership with BioLeonhardt Whole Body and other partners to develop a whole-body regeneration chamber, a “womb for adults”, that combines AI, advanced robotics, stem cells, amniotic fluid, placenta, nutrient hydrogel and regeneration-promoting growth factors, all supported by patented bioelectrically controlled protein expressions, stem cell homing, proliferation and differentiation control.

Lionheart Health, Inc., via its subsidiary, Lionheart Longevity & Wellness, plans to open 124 MedSpa clinics over the next 60 months that specialize in the convergence of medical aesthetics and physician-directed healthspan longevity protocols. Locations in New York City and Newport Beach, CA are currently open. Licensed sites in San Diego, Santa Barbara, Phoenix and Mexico are going through training certification with plans to fully launch this summer.

About Lionheart Health, Inc.:

Lionheart Health, Inc. is a 2022 spinout of Leonhardt Ventures LLC. Formed in 1982, Leonhardt Ventures LLC is a venture creation house and invention factory focused on organ regeneration and accelerating recovery. Leonhardt Ventures LLC supports an incubator lab and accelerator for bioelectric and biologic innovations. Over 600,000 patients have been treated with Leonhardt inventions since founding. Leonhardt Ventures has over 500 patent claims issued, pending, in-process, licensed or optioned related to organ regeneration and healthspan longevity.

Lionheart Health, Inc, Lionheart Longevity & Wellness Clinics

Contact: 
Howard Leonhardt: 1-949-669-8040, Email Contact
4740 Von Karman Avenue, Suite 150, Newport Beach, CA 92660

www.leonhardtventures.com | http://www.lionhearthealthstim.com | http://www.lionheartlongevity.com

R&D Lab: 5270 California Avenue, Irvine, CA 92617

¹ https://www.sciencedirect.com/science/article/pii/S1568163722002082

² https://www.nature.com/articles/s42003-024-06407-y

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Two industry innovation leaders have teamed up to transform the field of accelerated wound healing. The Lionheart Health, Inc. and ElectroMedical Technologies (OTC:EMED) joint venture combines Lionheart Health's patented bioelectric signaling software for regeneration and accelerated healing with ElectroMed's advanced device technology platform. This partnership is intended to make great leap strides in addressing critical patient needs such as avoiding limb amputation by significantly enhancing treatment outcomes in wound care.

Lionheart Health, Inc. is a spin out of Leonhardt Ventures LLC known for over 4 decades of breakthrough innovations in healthcare. Over 600,000 patients have been treated with Leonhardt inventions that generated over $2 billion in annual revenues for licensees and acquirers in 2024 alone.

Matthew Wolfson, CEO of ElectroMed Technologies, stated, "By integrating Lionheart Health's patented bioelectric accelerated healing protein expressions and our first in class device technology, we have created the ultimate accelerated wound healing solution that we believe is destined to transform patient wound care forward for the next 100 years. The encouraging results from our respective initial tests are a testament to the potential of this partnership. We believe this technology may contribute most in treating diabetic ulcers."

A Partnership of Continued Research and Commercialization

Following the promising safety and efficacy outcomes of pilot studies of both firms' wound healing products the joint venture is preparing to launch new combination clinical studies. The intended aim of these new studies is to significantly accelerate complete healing and long term outcomes in wound management and to prevent limb amputations.

A new planned wound care clinical study will have these arms (about to be submitted for independent IRB approval):

1. Bioelectric stimulation alone.

2. Bioelectric stimulation + bioelectric enhanced Super PRF TM.

3. Bioelectric stimulation + bioelectric enhanced Super PRF TM + amniotic sourced membrane grafts

4. All of the above (3) + stromal fraction derived from adipose tissue injections or klotho expressing stem cells (where available).

• PRF centrifuges for this study will be provided by BioPRF Florida https://bio-prf.com
• Adipose tissue processing devices will be provided by SynovaLife Pasadena https://www.synovalife.com

Lionheart Health-ElectroMed 240 Stimulator

In previous stand-alone pilot studies completed in patients with non-healing wounds on the soon to be amputated list in The Czech Republic, Mexico and the USA > 90% of limbs treated were saved.

Lionheart Health, Inc. has over 500 patent claims related to bioelectric protein expressions, tissue regeneration and accelerated healing. Electromedical Technologies founded in 2007 has over 18 years' experience developing and manufacturing electrical stimulation devices for treating pain and inflammation and other related disorders. The two organizations have a shared vision of enhancing patient outcomes in wound care and reducing long term care and lost opportunity costs for society. There are 185,000 amputations in the USA every year, most of them related to non-healing wounds, and this joint venture team has a goal to cut that by more than 1/2 within the decade.

Lionheart Health, Inc. is in the process of opening up, primarily via licensing, 124 clinics worldwide that will be trained and certified to practice their patented bioelectric treatment protocols. The plan is to make this wound care technology available to qualified clinics as an add on module license. The joint venture will receive 7% gross sales royalty on each patient service.

For more information visit: Lionheart Health and Electromedical Technologies.

Forward looking statements subject to change without notice.

Contacts

Howard Leonhardt: Email Contact

Mathew Wolfson: Email Contact

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Dec. 20th, 2024 - Irvine, California --(AINewsworthy)-- Leonhardt Ventures LLC is pleased to announce the issuance of U.S. Leonhardt et. al. Patent 12,109,410 with 15 claims entitled “Bioelectric Stimulator”, a significant advancement in the field of regenerative medicine. This patent, granted on October 8th, 2024, provides Lionheart Health, Inc., BioLeonhardt LTP, Valvublator, Inc., EyeCell, EarCell, KidneyCell, BladderCell, CerebraCell, CancerCell and other Leonhardt Ventures LLC spin out startups with exclusive rights to this pioneering patent for bioelectric stem cell homing, proliferation and differentiation control for regenerating tissues and organs and extending healthspan longevity.

Claims include a method of using a bioelectric stimulator to stimulate target tissue of a subject to control stem cell homing, proliferation, or differentiation and/or upregulate expression of at least one protein by the target tissue, wherein the protein is selected from the group consisting of activin, epidermal growth factor (EGF), follistatin, hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), platelet-derived growth factor (PDGF), receptor activator of nuclear factor kappa-B ligand (RANKL), stromal cell-derived factor 1 (SDF1), tropoelastin, vascular endothelial growth factor (VEGF) and any combination thereof.

This core platform technology is being applied to over 38 applications of use https://leonhardtventures.com/development-pipeline/ including (1) Heart & Cardiovascular, (2) Brain Health, (3) Major Organ Regeneration, (4) Medical Aesthetics and (5) Cancer.

Lionheart Health, Inc. http://www.lionhearthealthstim.com is applying this technology into its products and study protocols for skin and hair regeneration, body toning, sexual health, joint health and healthspan longevity.

BioLeonhardt http://www.bioleonhardt.com, Valvublator, Inc. and AortaCell to heart, heart valve and aorta regeneration.

CerebraCell http://www.cerebracell.com is applying it to applications for stroke and TBI recovery. MemoryStim http://www.memory-stim.com for applications in treating dementia and Alzheimer's in combination with klotho therapy.

PancreaCell, KidneyCell, RegenaLung and LiverCell are applying it to major organ regeneration https://leonhardtventures.com/major-organ-regeneration/. In the case of PancreaCell also as a treatment for diabetes. BladderCell to bladder health.

CancerCell http://www.cancercellinc.com is applying is cancer treatment.

"Being able to recruit stem cells where you want to when you want to in the body and then multiple them and control their differentiation is a major breakthrough in organ regeneration research" stated Dr. Jorge Genovese VP of Bioelectric Research.

About Leonhardt Ventures LLC:

Founded in 1982 Leonhardt Ventures LLC (HJ Leonhardt & Co.) is a long standing leader in the development of medical innovations. Over 600,000 patients have been treated with Leonhardt inventions to date http://www.leonhardtventures.com

Contacts:

Howard J. Leonhardt
Leonhardt Ventures LLC

Lionheart Health, Inc.
1 Kent Court
Mission Viejo, CA 92694
http://www.leonhardtventures.com

http://www.lionhearthealthstim.com

http://www.lionheartongevity.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Lionheart Health, Inc. announced today the appointments of Scott Hoots, Chad Hacker, and Tessa Sphar to its senior executive leadership team and Dr. Jwala Karnik to the Board of Directors.

“I am delighted to announce the addition of Scott, Chad, and Tessa to our executive leadership team and Dr. Jwala Karnik to our Board,” said Howard Leonhardt, Executive Chairman and co-CEO of Lionheart Health.

“We have worked diligently to build a best-in-class senior leadership team and board of directors as we hone our focus on opening up to 124 Lionheart Longevity & Wellness Medspas and EMS Fitness Studio locations worldwide over the next 60 months."

• Lionheart Longevity & Wellness MedSpa License Information >
  

• Lionheart BodStim TM EMS Fitness Studio License Information >

“Scott, Chad, Jwala, and Tessa are proven all-stars in our field of regenerative medicine and aesthetics. Scott led a team as CEO that opened over 200 regenerative medicine franchise locations. Chad helped lead Allergan Aesthetics into the digital marketing era and a $63 billion exit to Abbvie as VP of Consumer and Digital Marketing. Dr. Jwala Karnik newly elected Board Director was a key team member in helping to lead her previous firm to over $345 million in annual sales with a highly regarded Medspa skin treatment device. Tessa was the logistics leader in opening over 60 health and fitness franchise locations. This team brings an impressive track record into their new positions at Lionheart Health. We look forward to leveraging their expertise and insights as we grow Lionheart Health and advance our pipeline focused on regenerative aesthetics and healthspan longevity." Leonhardt further stated.

“I could not be more excited to be joining Lionheart Health a true technology innovator in our field,” said Scott Hoots, new co-CEO. “I look forward to working with the team to strengthen their ability to launch new locations with consistency. I share their commitment to mission purpose-based delivery of world-class one-of-a-kind patented technologies."

"What attracted me to Lionheart Health is their focus on the convergence of regenerative aesthetics and healthspan optimization," stated Dr. Jwala Karnik, Board Director. "I believe the future of beauty and healthcare is moving to personalized regenerative therapies. This is a great opportunity to join a proven core team that has led multiple products to industry leadership positions".

"Bioelectric protein expressions via homing stem cells to facial and neck tissue, building collagen, improving circulation and muscle tone, and improving elasticity are truly breakthroughs in skin regeneration. I joined Lionheart Health based on the promise of this technology to help improve the lives of millions" stated Chad Hacker, Board Director and Marketing Consultant

"Lionheart Health is determined to ensure every technology licensee delivers its patented technology platform to Medspa and fitness clinic clients in the best way possible. A commitment to world-class training. I am excited to join this team that has this mindset of doing things right from the beginning." stated Tessa Sphar, Lead Onboarding Specialist Consultant.

Lionheart Health, Inc. December of 2023 won the Allergan Aesthetics ULP Award for innovations in medical aesthetics and is an official entrant in the $101 million XPrize competition for healthspan extension.

LinkedIn Profiles New Members:

• Scott Hoots LinkedIn Profile >
• Chad Hacker LinkedIn Profile >
• Dr. Jwala Karnik LinkedIn Profile >
• Tessa Sphar LinkedIn Profile >

About Lionheart Health, Inc.

Lionheart Health, Inc. is focused on delivering best-in-class customized therapies for regenerative aesthetics and healthspan longevity extension primarily via highly trained licensed professionals. See Lionheart Longevity and Lionheart Health. Lionheart Health, Inc. is a spin-out of Leonhardt Ventures LLC that has been developing MedTech and biotech innovations for over 42 years. Over 600,000 patients have been treated with Leonhardt's inventions.

Contact email: Email Contact

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Lionheart Health, Inc,; the anticipated benefits of product candidates may not be realized, including expectations regarding therapeutic benefits, clinical potential and clinical development and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Lionheart Health may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Lionheart Health to timely and successfully achieve or recognize the anticipated benefits of commercialization, changes in applicable laws or regulation; the possibility that Lionheart Health may be adversely affected by other economic, business and/or competitive factors; Lionheart Health’s ability to advance product candidates on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring board; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop similar product and service treatments; maintaining or protecting intellectual property rights related to its product candidates; managing expenses; and raising the substantial additional capital needed, meeting timelines necessary, to continue development and market launch of product and service candidates Lionheart Health has proposed or may develop in the future. Lionheart Health may infringe patents of others and its own patents may be invalidated and patents pending may not be issued. Patent licenses may not be maintained. Lionheart Health anticipates that subsequent events and developments will cause Lionheart Health’s views to change sometime substantially. However, while Lionheart Health may elect to update these forward-looking statements at some point in the future, Lionheart Health specifically disclaims any obligation to do so, except as required by law.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

In a move to redefine the longevity and aesthetics industry and position Lionheart Health as the premier medical spa network in the world, the company today announced the grand opening ribbon cutting ceremony on June 21st, 2024 of a flagship 7-suite location in Newport Beach, California at 4740 Von Karman Avenue.

Lionheart Longevity and Wellness Medspas will offer a combination of the company’s proprietary bioelectric and biologic products for skin and hair regeneration as well as body toning and sculpting, joint/knee health, sexual health, bladder health, and healthspan optimization. The company’s proprietary products employ gentle bioelectric stimulation sequences and biologic compositions to engage the body’s natural healing processes to regenerate and repair itself.

At the center of Lionheart’s technology platform is increasing Klotho protein levels in the body, using a patented technology platform that has produced scientifically proven results in medically supervised clinical studies.

“At our medspa clinics, our goal is to utilize the power of safe and effective regenerative aesthetics technologies for skin, hair, body toning procedures and to introduce our patented healthspan optimization programs.” said Howard J. Leonhardt, Lead Inventor, Executive Chairman & CEO of Lionheart Health, Inc. “Opening a flagship 6 suite location in Newport Beach is a dream come true for our team that has worked so hard for so many years developing these unique technologies.”

Lionheart Longevity Orange County LLC, Chief Medical Director Dr. Sanjay Bhojraj commented, “We’re not just launching another medspa; we’re introducing innovative aesthetic and wellness services unavailable elsewhere. At the center of our patented regenerative technology is the ability to precisely control protein expressions to repair and reset cellular functions, including the Klotho protein.”

Klotho is an anti-aging protein predominantly produced in muscles and the kidney. Klotho’s benefits to the body have been widely studied and increasingly identified as a key to suppressing or even reversing many effects of aging. “Circulating levels of soluble Klotho decrease with age,” Dr. Leslie Miller Chief Medical Officer of Lionheart Health, Inc. stated. “This decline in Klotho gene expression is associated with an increased risk of age-related diseases.”

In addition to its patented bioelectric-enhanced treatments, Lionheart Health’s Longevity and Wellness MedSpas will offer conventional medspa services, including injectables, skin rejuvenation, lasers, microneedling and body toning, and robust client support designed to ensure each visit receives exceptional, personalized care.

Lionheart Health won the most recent AbbVie Allergan Aesthetics ULP Golden Passport Competition for Innovations in Medical Aesthetics, and is a contestant in the $101 million-dollar XPRIZE Competition for Healthspan Extension. v

The GRAND OPENING celebration will begin at 3:15 pm with a tour of the Lionheart Health, Inc. R&D Lab at 5270 California Avenue, 3rd Floor, University Lab Partners Section, Irvine, CA 92617. All guests after the R&D lab tour will get in their cars and drive just 5 minutes to 4740 Von Karman Avenue, Newport Beach for the ribbon cutting ceremony at the brand new Lionheart Longevity & Wellness MedSpa location. The event will end at 5:15pm.

• 3:15 pm: R&D Lab Tour @ 5270 California Avenue Irvine 3rd Floor
• 4:30 pm: MedSpa Tour and Ribbon Cutting Ceremony @ 4740 Von Karman Avenue, Newport Beach
• 5:15 pm: event ends (many will go to BossCat nearby for cocktails).

Experience the excitement of our grand opening by securing your free admission today through the Eventbrite link provided below. Leonhardt Vineyards wine and small food plates will be served at the event.

<<< Free Tickets Available Here >>>

Media Contact: Brian Hardy, (424) 291-2133, Email Contact

Web Sites:

lionheartlongevity.com

lionhearthealthstim.com

leonhardtventures.com

Howard J. Leonhardt

Executive Chairman & CEO

Lionheart Health, Inc.
Leonhardt Ventures LLC
1 Kent Court
Mission Viejo, CA 92694
www.leonhardtventures.com

email: Email Contact

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.